Prosecution Insights
Last updated: September 17, 2026
Application No. 18/428,728

Novel Stannic Protoporfin Compositions, Methods of Making, and Uses Thereof

Non-Final OA §103§112
Filed
Jan 31, 2024
Priority
Nov 07, 2023 — provisional 63/596,660
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Renibus Therapeutics Inc.
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
1m
Est. Remaining
71%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
878 granted / 1236 resolved
+11.0% vs TC avg
Minimal +0% lift
Without
With
+0.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
109 currently pending
Career history
1305
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
17.1%
-22.9% vs TC avg
§102
27.8%
-12.2% vs TC avg
§112
33.8%
-6.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1236 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions 2. Applicant’s election without traverse of Group I in the reply filed on June 25, 2026 is acknowledged. 3. The election of species is withdrawn. The full scope of the elected claims was searched and examined. Information Disclosure Statement 3. The information disclosure statements submitted on July 15, 2024 were in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98. The statements were considered. Signed copies of form 144 9 are enclosed herewith. Claim Objections 4. Claim 13 objected to for being dependent on a base withdrawn claim. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 5. Claim 2 recites the limitation "wherein the total impurity level is less than 1.5%." There is insufficient antecedent basis for this limitation in the claim. The independent claim recites an impurity level with units of wt.%. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 6. Claim(s) 1-7 and 13-15 is/are rejected under 35 U.S.C. 103 as being unpatentable over Land et al. The reference has a date of 1988 which antedates the present claims having a filing date of January 31, 2024 and priority claim to provisional application dated November 7, 2023. Determining the scope and contents of the prior art The reference teaches a composition comprising PNG media_image1.png 206 160 media_image1.png Greyscale in an aqueous solution. Ascertaining the differences between the prior art and the claims at issue The reference does not state the purity of the tin protoporphyrin that contains less than 1.0 wt% and a total impurity level below 3 wt%. Resolving the level of ordinary skill in the pertinent art - considering objective evidence present in the application indicating obviousness MPEP 2144.04 provides guidelines for the examination of applications and rationales for supporting an obviousness rejection. PNG media_image2.png 362 620 media_image2.png Greyscale Thus, the claims to a composition of PNG media_image1.png 206 160 media_image1.png Greyscale with a certain purity do not impart patentability to the claims based on the teaching of the composition itself. The skilled artisan has the motivation to employ purification methods that are known in the art to obtain purer compositions that have the same utility. The purifications are within the level of ordinary skill in the art. For this reason, it has been determined that the present claims are prima facie obvious over the prior art. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUN JAE YOO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jan 31, 2024
Application Filed
Sep 10, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735424
FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS
2y 5m to grant Granted Sep 15, 2026
Patent 12692253
Antimicrobial Compounds and Methods
5y 0m to grant Granted Jul 28, 2026
Patent 12690381
ORGANOMETALLIC COMPOUND AND APPLICATION THEREOF
2y 8m to grant Granted Jul 21, 2026
Patent 12674026
PROCESS FOR PREPARING POLYOL-BASED ESTERS OF ACYL-CAPPED HYDROXY CARBOXYLIC ACIDS
4y 6m to grant Granted Jul 07, 2026
Patent 12661353
SPT5 INHIBITORS AND USES THEREOF
4y 10m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
71%
With Interview (+0.3%)
2y 8m (~1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1236 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month